{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:37:03Z","timestamp":1790498223815,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bcmd.2020.102530","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T03:21:33Z","timestamp":1607397693000},"page":"102530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["The potential role of emicizumab prophylaxis in severe von Willebrand disease"],"prefix":"10.1016","volume":"87","author":[{"given":"Assaf A.","family":"Barg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Avishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar Barazani","family":"Brutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Tamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Bashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudi","family":"Misgav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadan","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2020.102530_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2020.102530_bb0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2020.102530_bb0015","first-page":"391","article-title":"A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus."},{"key":"10.1016\/j.bcmd.2020.102530_bb0020","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.bcmd.2020.102530_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia a with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2020.102530_bb0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2020.102530_bb0035","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcmd.2020.102530_bb0040","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3324\/haematol.11460","article-title":"Thrombin-generating capacity in patients with von Willebrand\u2019s disease","volume":"92","author":"Rugeri","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2020.102530_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/09537104.2019.1581922","article-title":"Platelets compensate for poor thrombin generation in type 3 von Willebrand disease","volume":"31","author":"Szanto","year":"2020","journal-title":"Platelets."},{"key":"10.1016\/j.bcmd.2020.102530_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia a and inhibitors-a single-center cohort","volume":"66","author":"Barg","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2020.102530_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a pediatric cohort: real-world data","author":"Barg","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102530_bb0060","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.bcmd.2020.102530_bb0065","series-title":"4th Scientific Meeting of the Thrombosis and Hemostasis Societies of North America (THSNA) April 22\u201325","article-title":"Evaluation of a dedicated calibrator and controls for Emicizumab quantification","author":"Calhoon","year":"2018"},{"key":"10.1016\/j.bcmd.2020.102530_bb0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.bcmd.2020.102530_bb0075","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand disease prophylaxis network","volume":"13","author":"Abshire","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2020.102530_bb0080","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bcmd.2020.102530_bb0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand disease prophylaxis network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bcmd.2020.102530_bb0090","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.bcmd.2020.102530_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102530_bb0100","doi-asserted-by":"crossref","first-page":"102416","DOI":"10.1016\/j.bcmd.2020.102416","article-title":"Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: effects of bypassing agents and antithrombin reduction","volume":"82","author":"Livnat","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2020.102530_bb0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2020.102530_bb0110","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/hae.13871","article-title":"ST-segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia a patient receiving emicizumab and recombinant activated factor VII","volume":"26","author":"Gundabolu","year":"2020","journal-title":"Haemophilia."},{"key":"10.1016\/j.bcmd.2020.102530_bb0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613227","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2020.102530_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MBC.0000000000000179","article-title":"Venous thrombosis in von Willebrand disease as observed in one Centre and as reported in the literature","volume":"26","author":"Girolami","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bcmd.2020.102530_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia."},{"key":"10.1016\/j.bcmd.2020.102530_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/hae.13677","article-title":"Moderate haemophilia in focus","volume":"25","author":"Berntorp","year":"2019","journal-title":"Haemophilia."},{"key":"10.1016\/j.bcmd.2020.102530_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5482\/HAMO-14-12-0081","article-title":"Interaction of von Willebrand factor with platelets and the vessel wall","volume":"35","author":"Ruggeri","year":"2015","journal-title":"Hamostaseologie."},{"key":"10.1016\/j.bcmd.2020.102530_bb0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"De Wee","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2020.102530_bb0145","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.24195","article-title":"Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding","volume":"90","author":"Sanders","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2020.102530_bb0150","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1111\/hae.12733","article-title":"Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype","volume":"21","author":"van Meegeren","year":"2015","journal-title":"Haemophilia."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620305672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620305672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:19Z","timestamp":1761050179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979620305672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"alternative-id":["S1079979620305672"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102530","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of emicizumab prophylaxis in severe von Willebrand disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102530"}}